207 related articles for article (PubMed ID: 30777660)
1. Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives.
Yu Z; Chen Z; Su Q; Ye S; Yuan H; Kuai M; Lv M; Tu Z; Yang X; Liu R; Hu G; Li Q
Bioorg Med Chem; 2019 Mar; 27(6):944-954. PubMed ID: 30777660
[TBL] [Abstract][Full Text] [Related]
2. 9za plays cytotoxic and proapoptotic roles and induces cytoprotective autophagy through the PDK1/Akt/mTOR axis in non-small-cell lung cancer.
Liu R; Chen Z; Yi X; Huang F; Hu G; Liu D; Li X; Zhou H; Liu Z
J Cell Physiol; 2019 Nov; 234(11):20728-20741. PubMed ID: 31004362
[TBL] [Abstract][Full Text] [Related]
3. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
5. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
6. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
Falasca M; Chiozzotto D; Godage HY; Mazzoletti M; Riley AM; Previdi S; Potter BV; Broggini M; Maffucci T
Br J Cancer; 2010 Jan; 102(1):104-14. PubMed ID: 20051961
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between PI3 kinase/PDK1/Akt/Rac1 and Ras/Raf/MEK/ERK pathways downstream PDGF receptor.
Niba ET; Nagaya H; Kanno T; Tsuchiya A; Gotoh A; Tabata C; Kuribayashi K; Nakano T; Nishizaki T
Cell Physiol Biochem; 2013; 31(6):905-13. PubMed ID: 23817184
[TBL] [Abstract][Full Text] [Related]
8. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.
Li Q; Wu J; Zheng H; Liu K; Guo TL; Liu Y; Eblen ST; Grant S; Zhang S
Bioorg Med Chem Lett; 2010 Aug; 20(15):4526-30. PubMed ID: 20580230
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
11. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
12. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
[TBL] [Abstract][Full Text] [Related]
14. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
15. SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling.
Bao F; An S; Yang Y; Xu TR
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107587
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.
Sestito S; Nesi G; Daniele S; Martelli A; Digiacomo M; Borghini A; Pietra D; Calderone V; Lapucci A; Falasca M; Parrella P; Notarangelo A; Breschi MC; Macchia M; Martini C; Rapposelli S
Eur J Med Chem; 2015 Nov; 105():274-88. PubMed ID: 26498573
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions.
Yang L; Guo W; Zhang Q; Li H; Liu X; Yang Y; Zuo J; Liu W
J Mol Biol; 2011 Dec; 414(5):654-66. PubMed ID: 21964438
[TBL] [Abstract][Full Text] [Related]
20. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
